Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

Extramural Funding Opportunities

The following is a list of currently open non-limited extramural funding opportunties. Listings are generally updated in batches on a monthly basis. Entries are ordered by posting date, with most recent postings first. All funding opportunities are removed from this list once their final application due date has passed.

  

Posted June 6, 2014

Gabrielle’s Angel Foundation 2014 Conventional and Integrative Grants

Application Due Date(s):  Proposal to JCCC due June 23, 2014 / Application due August 15, 2014

How to Apply: Download the application here

Description: Gabrielle’s Angel Foundation for Cancer Research is soliciting grant applications to fund innovative and insightful medical research on the hematologic malignancies. Gabrielle’s Angel has focused on supporting promising junior investigators conducting scientific research that can be applied to improving the treatment of patients with these diseases. Gabrielle’s Angel has invited the JCCC to nominate a total of two junior faculty members, one each for their Conventional and Integrative grants.

  • Conventional Grant: Conventional or mainstream projects that can be applied to improving treatment of patients with hematologic malignancies.
  • Integrative Grant: Integrative research projects that explore evidence-based complementary interventions such as acupuncture, nutrition, meditation, yoga, etc. Also supports clinical trials and/or pre-clinical research that addresses reducing patients’ physical and emotional distress during or after cancer therapy

The award for each grant is $75,000 a year for three years. Overhead/indirect costs may not exceed 10 percent of the total grant award.

 

Posted May 15, 2014

Damon Runyon Cancer Research Foundation 2014 Damon Runyon-Rachleff Innovation Award

Application Due Date(s):  July 1, 2014

How to Apply: Visit the website by clicking here

Description: The Innovation Award is designed to provide support for the next generation of exceptionally creative early career researchers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. It is specifically designed to support researchers who have an innovative new idea but lack sufficient preliminary date to obtain traditional funding. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

This award provides $150,000 per year for three years in direct research costs. The Award cannot be used for indirect costs or institutional overhead. The Innovation Award Committee will consider an accelerated payment schedule if an award recipient can demonstrate compelling need.

Since the goal of the Innovation Award is to fund high risk/high reward research that lacks sufficient preliminary data to secure traditional funding, the applicant should not have funding for this proposed project. During the course of the award, award recipients are encouraged to seek additional funding to expand and further develop their projects.

Alex’s Lemonade Stand Foundation (ALSF) 2014 Bio-Therapeutics Impact Award (BTIA) 

Application Due Date(s): June 12, 2014

How to Apply: Download the PDF here

Description: This award provides funding to support investigator-initiated clinical trials using biologic therapies, including but not limited to immunotherapy, gene therapy and small molecules. This grant category was initiated to accelerate the development of clinical trials for promising biologic approaches to treat childhood cancers through clinical trials.

A maximum of $1.5 million in total costs will be awarded over three years ($500,000 per year for three years). If applying for pre-clinical funding to perform IND enabling studies or have submitted an IND and are awaiting approval, funding will be capped at $100,000 in year one and the balance for the clinical trial initiation will be released after the IND is approved. The purchase of equipment is capped at $250,000 over three years.

Cutaneous Lymphoma Foundation CLARIONS Research Awards Program

Application Due Date(s): July 31, 2014

How to Apply: Visit the website here

Description: This award supports investigators interested in conducting innovative cutaneous lymphoma research designed to investigate the causes and improve the treatment, multimodality care and quality of life for patients. The aim is to discover new avenues for better therapies and, one day, a cure for cutaneous lymphoma.

This award provides $25,000 for one year, renewable for one additional year contingent upon approval by the CLF Board of Directors based upon the CLF Scientific Review Board’s review and recommendation. A small indirect cost amount between $1,000-$2,000 is allowable.

The Cure Starts Now Foundation 2014 Grant – DIPG Collaborative 

Application Due Date(s): July 31, 2014

How to Apply: Download the PDF here

Description: The Cure Starts Now Foundation is a non-profit charity dedicated to educating, aiding and funding the search for a cure for brainstem glioma and other forms of pediatric brain cancer in the hopes of curing all cancers. The Foundation seeks to fund research investigating cures for pediatric brain cancers with a focus on Diffuse Intrinsic Brainstem Glioma (DIPG). Our focus is to support translational and clinical research projects in those areas.

This award provides up to $100,000 for one year of direct costs related to the research project. No indirect or travel costs are allowed. Support of salary must not exceed percentage of effort related to the research project and may not exceed 10% of the total funded amount. 

 

Posted April 16, 2014

2015 Vilcek Prizes for Creative Promise in Biomedical Science

Application Due Date(s):  June 10, 2014

How to Apply: A written application, professional résumé, list of publications, and letters of recommendation are required. Eligibility requirements and a link to the online application can be found at Vilcek.org.

Description: The Vilcek Foundation is seeking applications for the 2015 Vilcek Prizes for Creative Promise in Biomedical Science. Three foreign-born biomedical scientists will be selected to receive the prizes, each including a cash award of $50,000.

Established in 2009, the Vilcek Prizes for Creative Promise raise public awareness of the key role foreign-born researchers play in sustaining the leadership position of the United States in the sciences; the prizes also serve to support younger scientists who have distinguished themselves early in their careers.

Researchers in all fields of biomedical science are encouraged to apply. Applicants must have been born abroad, be naturalized citizens or permanent residents of the United States, hold a doctoral degree, intend to pursue a career in the United States, and be no more than 38 years old as of December 31, 2014. In addition, they must also hold a full-time independent position at an academic institution or other organization. 

Ovarian Cancer Research Fund 2015 Program Project Development Grant

Application Due Date(s): Letter of Intent due May 6, 2014 / Full proposal due August 1, 2014

How to Apply: Download the PDF here. All LOI’s must be submitted via the ProposalCENTRAL website (https://proposalcentral.altum.com/).

Description: The purpose of this program is to provide funds for ovarian cancer research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Applications that are creative, original, and hold the most promise in the areas of screening and early detection, etiology and prevention, molecular therapeutics, cancer biology and genetics are favorable.

The Ovarian Cancer Research Fund will award $300,000 annually for three years. Award recipients are required to submit annual progress reports (narrative and financial) throughout the award cycle. 

Ovarian Cancer Research Fund 2015 Liz Tilberis Early Career Award 

Application Due Date(s): Letter of Intent due May 6, 2014 / Full proposal due August 1, 2014

How to Apply: Download the PDF here. All LOI’s must be submitted via the ProposalCENTRAL website (https://proposalcentral.altum.com/).

Description: The Liz Tilberis Early Career Award is directed towards junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these awards is to support a substantial time commitment to research and academic endeavors in ovarian cancer. The selection committee will favorably consider applications that are creative, original, and hold the most promise in the areas of early detection, prevention, treatment, and translational ovarian cancer research.

The Liz Tilberis Early Career Award will provide funds of $150,000 per year for three years. The investigator and institution must certify that at least 75% of the scholar’s time will be dedicated to ovarian cancer research. Award recipients will be required to submit annual progress reports (narrative and financial) throughout the award cycle.

Ovarian Cancer Research Fund 2015 Ann Schreiber Mentored Investigator Award

Application Due Date(s): Letter of Intent due May 6, 2014 / Full proposal due August 1, 2014

How to Apply: Download the PDF here. All LOI’s must be submitted via the ProposalCENTRAL website (https://proposalcentral.altum.com/).

Description: This award provides funds for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research, or relevant area. The selection committee will consider the strength of the research environment and project proposal, the trainee’s prior academic track record, and the likelihood of his/her pursuing a research career dedicated to ovarian cancer. The proposed research plan should have sufficient scientific depth to potentially lead to publication of results in high quality journals. Ideally, the project proposed should be one that the trainee’s mentor believes will advance the overall scientific objectives of the group.

The Ann Schreiber Mentored Investigator Award provides a total of $75,000, to be used over one or two years. Although the trainee may take part in some non-research activities (e.g. class work, clinical activities) at least 90% effort should be devoted to research during the tenure of the OCRF award. IRB/IACUC approval will be verified at time of award (do not include with application).

Lung Cancer Research Foundation 2014 Grant

Application Due Date(s): June 16, 2014

How to Apply: Download the PDF here

Description: The Lung Cancer Research Foundation's grant program provides critical seed support for cutting-edge scientific research on all cancers of the lung. The LCRF believes that this type of support can build proof of concept for researchers to apply for additional grant funding from universities and public sources. Lung cancer projects can be focused on basic science, translational research, clinical research, supportive care, and quality of care/outcomes.

This award provides up $50,000 for one year. All applicable costs including indirect/overhead costs must be included as part of requested budget total. Personnel budget lines must not account for more than 15% of total request. Funds may not be used for direct patient care costs that could be reimbursed from other sources.

 

Posted March 4, 2014

American Society of Hematology Scholar Award

Application Due Date(s): Letter of Intent due May 1, 2014 / Application due August 1, 2014

How to Apply: Visit the website here

Description: The ASH Scholar Award provides funding to support hematologists who have chosen career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator. This award supports both basic/translational research and clinical research.

This award provides a maximum of $100,000 for fellow scholars and $150,000 for junior faculty scholars over a two- to three-year period, with an annual maximum of $50,000 for fellows and $75,000 for junior faculty. Up to 15 percent of the award may be (but is not required to be) used for benefits, including medical and dental insurance, life insurance, and retirement benefits. 

    

Posted December 20, 2013

NIH Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes

Application Due Date(s): September 8, 2014

How to Apply: Visit the website here

Description: This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes.

Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on assays that provide new insight into important disease targets and processes.

NIH Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes

Application Due Date(s): September 8, 2014

How to Apply: Visit the website here

Description: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds.

Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on assays that provide new insight into important disease targets and processes.

   

Posted February 16, 2012

PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])

ID: PA-12-089

Application Due Date(s): Standard dates apply (see website)

How to Apply: Available on website: http://grants.nih.gov/grants/guide/pa-files/PA-12-089.html

Description: This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics.

New Technologies for Viral Hepatitis SBIR (R43/R44)

ID: PA-12-090

Application Due Date(s): Standard dates apply (see website)

How to Apply: See website at http://grants.nih.gov/grants/guide/pa-files/PA-12-090.html 

Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to respond to the Combating the Silent Epidemic of Viral Hepatitis: U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (Viral Hepatitis Action Plan) which was released on May 12, 2011 (http://www.hhs.gov/ash/initiatives/hepatitis/). SBCs are encouraged to propose SBIR grant applications to develop resources, research tools, instrumentations, biomarkers, devices, drugs or new and innovative approaches to diagnosis, monitoring, management, treatment and prevention of viral hepatitis and viral hepatitis associated liver disease.

New Technologies for Viral Hepatitis STTR (R41/R42)

ID: PA-12-091

Application Due Date(s): Standard dates apply (see website)

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PA-12-091.html

Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose to respond to the Combating the Silent Epidemic of Viral Hepatitis: U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (Viral Hepatitis Action Plan) which was released on May 12, 2011 (http://www.hhs.gov/ash/initiatives/hepatitis/). SBCs are encouraged to propose STTR grant applications to develop resources, research tools, instrumentations, biomarkers, devices, drugs or new and innovative approaches to diagnosis, monitoring, management, treatment and prevention of viral hepatitis and viral hepatitis associated liver disease.

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21)

ID: PAR-12-094

Application Due Date(s): Standard dates apply (see website)

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-094.html

Description: Through this Funding Opportunity Announcement (FOA), the Center to Reduce Cancer Health Disparities (CRCHD) and the Division of Cancer Biology (DCB), at the National Cancer Institute (NCI), invite grant applications from investigators interested in conducting basic research studies into the biological causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies, development and testing of new methodologies, secondary data analyses, and innovative mechanistic studies that investigate biological/genetic bases of cancer health disparities. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research and to provide resources for those investigators that may need additional support on their path to successfully compete for R01 funding in basic mechanistic research in understanding cancer health disparities.

Basic Cancer Research in Cancer Health Disparities (U01)

ID: PAR-12-095

Application Due Date(s): November 20, 2013; June 20, 2014; November 20, 2014 , by 5:00 PM local time of applicant organization.

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-095.html

Description: Through this Funding Opportunity Announcement (FOA), the Center to Reduce Cancer Health Disparities (CRCHD), the Division of Cancer Biology (DCB) and Division of Cancer Prevention (DCP), at the National Cancer Institute (NCI), encourage grant applications from investigators interested in conducting basic, mechanistic research into the biologic/genetic causes of cancer health disparities. These cooperative agreement research awards (U01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, and may include the development and testing of new methodologies and models, secondary data analyses, and mechanistic studies of identified biological factors associated with cancer disparities, including those related to basic research in prevention strategies. This FOA is also designed to aid and facilitate the development of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can develop resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.

 

Posted Dec. 5, 2011

Small Grants Program for Cancer Epidemiology (R03)

ID: PAR-12-039

Application Due Date(s): July 22, 2014; November 18, 2014, by 5:00 PM local time of applicant organization.

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-039.html

Description: This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), encourages the submission of Small Research Grant (R03) applications for research on cancer etiology and epidemiology. The overarching goal of this FOA is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.

Using the NIH Small Research Grant (R03) funding mechanism, this FOA focuses on different types of projects including, but not limited to: (1) pilot and feasibility studies; (2) secondary analysis of existing data; (3) small, self-contained research projects; (4) development of research methodology; and (5) development of new research technology. The R03 mechanism is critical for collection of pilot data that can be used for larger grant applications such as the Research Project Grant Mechanism (R01). R01 studies in cancer epidemiology usually require large sample sizes, complex logistics, extensive fieldwork, acquisition of biospecimens, and, sometimes, the acquisition of sensitive information such as reproductive histories.

Cancer Education Grants Program (R25)

ID: PAR-12-049

Application Due Date(s): Standard dates apply (see schedule)

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-049.html

Description: The NIH Research Education (R25) grant mechanism supports creative and innovative research education programs for the development of biomedical, behavioral, and clinical researchers, or for education and outreach on health-related research to a variety of audiences. Research education grants are not typical research instruments. The awards are intended to support institutional educational programs but not research projects. Applications must include a plan to evaluate the educational activities proposed (see Section IV, Evaluation Plan) and a plan for disseminating results (see Section IV, Dissemination Plan). The NCI uses this FOA to support innovative institutional educational programs in the mission area(s) of the National Cancer Institute (http://strategicplan.nci.nih.gov/).

 

Posted Aug. 5, 2011

Center for Inherited Disease Research (CIDR) High Throughput Genotyping and Sequencing Resource Access (X01)

ID: PAR-11-210

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-11-210.html

Application Due Date: Applications are accepted by continuous receipt.

Description: This FOA is seeking projects that show promise of identifying genetic element(s) important to human health and disease. CIDR high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes that contribute to human health and disease. The services provided through CIDR focus primarily on needs that can’t be readily handled by individual investigator laboratories. CIDR provides the most up-todate platforms and services. This is an NIH-wide initiative that is managed by NHGRI. There should be strong evidence that the project proposed is likely to have the power to detect genetic factors affecting the trait under study. In addition, there should be a clear need for the particular high-throughput service requested. Appropriate projects would include but not be limited to: Human GWAS studies for common human diseases; human and mouse genome-wide linkage analyses, whole genome sequencing, whole-exome and custom-targeted DNA sequencing, analyses of DNA methylation and custom SNP genotyping. Offered through the National Cancer Institute.

  

Last updated: 6/6/2014 2:54:17 PM